Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $1.15B
• Dividend Yield: N/A
• Average Volume (3M): 2.78M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 53.28%
• EPS Growth: 21.77%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.14
• Shares Outstanding: 134,677,100
• 10 Day Avg. Volume: 2,929,000
• 30 Day Avg. Volume: 2,780,866
• PEG Ratio: -0.25
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 8.02
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 13.66
• Enterprise Value/Gross Profit: 13.91
• Enterprise Value/Ebitda: -8.74
• 1Y Price Target: $13.67
• Price Target Upside: 60.26% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.87
• Revenue Forecast (FY): $62.95M

• Rating: 59 Neutral
• Price Target: $10.00 ▲(17.23% Upside)

Tango Therapeutics' overall stock score is driven by strong technical indicators and positive corporate events, which offset the financial performance challenges. The recent capital raise significantly enhances its financial stability and growth potential, while technical trends suggest a favorable market sentiment. However, ongoing profitability and cash flow issues remain a concern.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product acceptance, which is crucial for sustaining long-term business expansion.

Capital Raise

The capital raise enhances financial stability and supports strategic growth, allowing Tango to advance its pipeline and strengthen its market position.

Strategic Partnerships

Strategic partnerships provide a steady revenue stream and access to resources, enhancing Tango's ability to innovate and compete in the biotech industry.

Negative Factors

Profitability Challenges

Ongoing profitability issues can hinder long-term sustainability, requiring focused efforts on cost management and revenue enhancement to achieve financial stability.

Negative Cash Flow

Negative cash flow impacts liquidity and limits the company's ability to invest in growth opportunities, posing a risk to long-term operational viability.

Negative Return on Equity

A negative return on equity suggests inefficiencies in using shareholder funds, which can deter investment and affect the company's growth prospects.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements for its proprietary drug candidates. Additionally, the company may receive milestone payments as its products progress through various stages of development and regulatory approval. Revenue may also come from grants and funding from research institutions or government bodies aimed at supporting its research initiatives. The company’s ability to monetize its intellectual property and the success of its therapeutic candidates in clinical trials are significant factors contributing to its earnings.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics demonstrates strong revenue growth and efficient cost management, as seen in its high gross profit margin. However, the company faces significant profitability challenges with persistent losses and negative cash flows. While leverage is low, the negative return on equity and cash flow issues suggest financial instability. Continued focus on improving profitability and cash flow is essential for future stability.

Income Statement

Tango Therapeutics shows a strong gross profit margin, indicating efficient cost management. However, the company struggles with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is notable, especially in the TTM period, but profitability remains a challenge.

Balance Sheet

The company's debt-to-equity ratio is relatively low, suggesting manageable leverage. However, the negative return on equity indicates that the company is not generating profit from its equity base. The equity ratio is stable, showing a solid equity position relative to total assets.

Cash Flow

Tango Therapeutics faces negative operating and free cash flows, which are concerning for liquidity. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income losses. The negative growth in free cash flow highlights cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	66.50M	42.07M	36.53M	24.86M	37.04M	7.66M
Gross Profit	65.32M	42.07M	36.53M	24.86M	37.04M	6.03M
EBITDA	-103.96M	-143.10M	-111.76M	-109.46M	-57.29M	-50.35M
Net Income	-100.52M	-130.30M	-101.74M	-108.18M	-58.23M	-51.97M
Balance Sheet
Total Assets	210.14M	316.49M	402.57M	436.47M	500.15M	207.25M
Cash, Cash Equivalents and Short-Term Investments	152.81M	257.92M	336.88M	366.13M	485.25M	190.32M
Total Debt	34.76M	36.49M	38.92M	41.13M	1.50M	7.88M
Total Liabilities	50.10M	116.97M	149.46M	186.99M	155.41M	168.65M
Stockholders Equity	160.03M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow
Free Cash Flow	-146.76M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
Operating Cash Flow	-145.81M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
Investing Cash Flow	146.91M	86.13M	41.43M	26.40M	-183.43M	-145.47M
Financing Cash Flow	4.09M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.53
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Neutral. The current price of 8.53 is below the 20-day moving average (MA) of 9.46, below the 50-day MA of 8.79, and above the 200-day MA of 5.60, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 8.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNGX	59 Neutral	$1.15B	-9.31	-51.65%	―	53.28%	21.77%
SPRY	57 Neutral	$1.09B	-13.61	-45.92%	―	5459.66%	-59.70%
IMTX	56 Neutral	$1.37B	-9.34	-29.01%	―	-27.61%	-69.49%
UPB	52 Neutral	$1.58B	-12.79	-40.80%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRME	43 Neutral	$666.08M	-2.50	-112.34%	―	647.13%	26.79%
ORKA	41 Neutral	$1.54B	-13.12	-23.05%	―	―	63.85%

Tango Therapeutics Corporate Events

Tango Therapeutics Enters New Sales Agreement with Leerink

On November 21, 2025, Tango Therapeutics entered into a Sales Agreement with Leerink Partners LLC to sell up to $100 million of its common stock through an at-the-market offering. This move follows the termination of a previous sales agreement with Jefferies LLC, effective the same day, indicating a shift in the company’s strategy for raising capital.

Tango Therapeutics Announces Major Stock Offering

On October 23, 2025, Tango Therapeutics announced a registered direct offering of 21,023,337 shares of common stock and pre-funded warrants to purchase an additional 3,226,458 shares, expected to raise approximately $197 million. The proceeds will be used to advance the company’s pipeline and support general corporate purposes, with the offering anticipated to close on October 24, 2025. Additionally, Tango entered into a private placement agreement with an accredited investor for 1,732,101 shares, expected to generate $15 million. These financial moves are intended to fund operations and capital expenditures into 2028, strengthening Tango’s position in the biotechnology industry.

Tango Therapeutics Announces Preliminary Financial Results

On October 23, 2025, Tango Therapeutics announced preliminary unaudited financial results, estimating $152.8 million in cash and marketable securities as of September 30, 2025. The company also provided a clinical update on its ongoing Phase 1/2 trial of vopimetostat, highlighting its potential as a best-in-class treatment for MTAP-deleted solid tumors, with plans for a pivotal study in second-line pancreatic cancer to begin in 2026.